MedTrace Logo

Study of CVN424 in Healthy Subjects

NCT03657030 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-07-23

No results posted yet for this study

Summary

This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

CVN424

SAD / MAD

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Cerevance Beta, Inc.

    lead INDUSTRY

Principal Investigators

  • David H Margolin, MD, PhD · Cerevance, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-18
Primary Completion
2019-03-01
Completion
2019-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657030 on ClinicalTrials.gov